Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Amatruda

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Journal of Diabetes|June 30, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetesAdrian S Dobs, Barry J Goldstein, Pablo Aschner, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Journal of Diabetes|June 30, 2012
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetesAdrian S Dobs, Barry J Goldstein, Pablo Aschner, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 9